Selecta Biosciences (NASDAQ: SELB) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Valuation & Earnings

This table compares Selecta Biosciences and Exelixis’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Selecta Biosciences $4.14 million 115.12 -$51.16 million ($2.87) -7.52
Exelixis $319.67 million 23.85 $95.32 million $0.19 136.53

Exelixis has higher revenue and earnings than Selecta Biosciences. Selecta Biosciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Selecta Biosciences has a beta of -6.02, suggesting that its stock price is 702% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Selecta Biosciences and Exelixis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Selecta Biosciences 0 0 3 0 3.00
Exelixis 0 6 6 0 2.50

Selecta Biosciences presently has a consensus price target of $28.33, indicating a potential upside of 31.23%. Exelixis has a consensus price target of $29.57, indicating a potential upside of 14.00%. Given Selecta Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Selecta Biosciences is more favorable than Exelixis.

Insider and Institutional Ownership

53.5% of Selecta Biosciences shares are held by institutional investors. Comparatively, 79.2% of Exelixis shares are held by institutional investors. 41.9% of Selecta Biosciences shares are held by company insiders. Comparatively, 5.1% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Selecta Biosciences and Exelixis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Selecta Biosciences -61,411.54% -107.39% -67.10%
Exelixis 18.20% 80.43% 13.93%

Summary

Exelixis beats Selecta Biosciences on 9 of the 13 factors compared between the two stocks.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Exelixis Company Profile

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company’s CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company’s XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.